{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T09:35:35Z","timestamp":1782207335108,"version":"3.54.5"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2019,4,27]],"date-time":"2019-04-27T00:00:00Z","timestamp":1556323200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s10620-019-05635-1","type":"journal-article","created":{"date-parts":[[2019,4,27]],"date-time":"2019-04-27T08:01:53Z","timestamp":1556352113000},"page":"3066-3077","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Strategies to Optimize Anti-tumor Necrosis Factor Therapy for Perianal Fistulizing Crohn\u2019s Disease: A Systematic Review"],"prefix":"10.1007","volume":"64","author":[{"given":"Parul","family":"Tandon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glara Gaeun","family":"Rhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey D.","family":"McCurdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,27]]},"reference":[{"key":"5635_CR1","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1136\/gut.37.5.696","volume":"37","author":"F Makowiec","year":"1995","unstructured":"Makowiec F, Jehle EC, Starlinger M. Clinical course of perianal fistulas in Crohn\u2019s disease. Gut. 1995;37:696\u2013701.","journal-title":"Gut"},{"key":"5635_CR2","first-page":"445","volume":"11","author":"CC Dias","year":"2017","unstructured":"Dias CC, Rodrigues PP, Coelho R, et al. Development and validation of risk matrices for Crohn\u2019s disease outcomes in patients who underwent early therapeutic interventions. J Crohns Colitis. 2017;11:445\u2013453.","journal-title":"J Crohns Colitis"},{"key":"5635_CR3","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1136\/gut.21.6.525","volume":"21","author":"G Hellers","year":"1980","unstructured":"Hellers G, Bergstrand O, Ewerth S, Holmstrom B. Occurrence and outcome after primary treatment of anal fistulae in Crohn\u2019s disease. Gut. 1980;21:525\u2013527.","journal-title":"Gut"},{"key":"5635_CR4","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1053\/gast.2002.32362","volume":"122","author":"DA Schwartz","year":"2002","unstructured":"Schwartz DA, Loftus EVJ, Tremaine WJ, et al. The natural history of fistulizing Crohn\u2019s disease in Olmsted County, Minnesota. Gastroenterology. 2002;122:875\u2013880.","journal-title":"Gastroenterology"},{"key":"5635_CR5","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3748\/wjg.v12.i1.75","volume":"12","author":"A Lapidus","year":"2006","unstructured":"Lapidus A. Crohn\u2019s disease in Stockholm County during 1990\u20132001: an epidemiological update. World J Gastroenterol. 2006;12:75\u201381.","journal-title":"World J Gastroenterol"},{"key":"5635_CR6","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.cgh.2006.06.021","volume":"4","author":"LY Tang","year":"2006","unstructured":"Tang LY, Rawsthorne P, Bernstein CN. Are perineal and luminal fistulas associated in Crohn\u2019s disease? A population-based study. Clin Gastroenterol Hepatol. 2006;4:1130\u20131134.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"5635_CR7","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1136\/gut.2008.159251","volume":"58","author":"JF Colombel","year":"2009","unstructured":"Colombel JF, Schwartz DA, Sandborn WJ, et al. Adalimumab for the treatment of fistulas in patients with Crohn\u2019s disease. Gut. 2009;58:940\u2013948.","journal-title":"Gut"},{"key":"5635_CR8","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","volume":"340","author":"DH Present","year":"1999","unstructured":"Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn\u2019s disease. N Engl J Med. 1999;340:1398\u20131405.","journal-title":"N Engl J Med"},{"key":"5635_CR9","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa030815","volume":"350","author":"BE Sands","year":"2004","unstructured":"Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn\u2019s disease. N Engl J Med. 2004;350:876\u2013885.","journal-title":"N Engl J Med"},{"key":"5635_CR10","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1136\/gutjnl-2013-306709","volume":"63","author":"KB Gecse","year":"2014","unstructured":"Gecse KB, Bemelman W, Kamm MA, et al. A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn\u2019s disease. Gut. 2014;63:1381\u20131392.","journal-title":"Gut"},{"key":"5635_CR11","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/ajg.2011.73","volume":"106","author":"AC Ford","year":"2011","unstructured":"Ford AC, Sandborn WJ, Khan KJ, Hanaeur SB, Talley NJ, Moayyedi P. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106:644\u2013659.","journal-title":"Am J Gastroenterol"},{"key":"5635_CR12","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.3748\/wjg.v21.i8.2475","volume":"21","author":"B-L Yang","year":"2015","unstructured":"Yang B-L, Chen Y-G, Gu Y-F, et al. Long-term outcome of infliximab combined with surgery for perianal fistulizing Crohn\u2019s disease. World J Gastroenterol. 2015;21:2475\u20132482.","journal-title":"World J Gastroenterol"},{"key":"5635_CR13","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/MCG.0000000000000169","volume":"49","author":"C Castano-Milla","year":"2015","unstructured":"Castano-Milla C, Chaparro M, Saro C, et al. Effectiveness of adalimumab in perianal fistulas in Crohn\u2019s disease patients naive to anti-TNF therapy. J Clin Gastroenterol. 2015;49:34\u201340.","journal-title":"J Clin Gastroenterol"},{"key":"5635_CR14","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1007\/s10620-008-0545-y","volume":"54","author":"D Tougeron","year":"2009","unstructured":"Tougeron D, Savoye G, Savoye-Collet C, Koning E, Michot F, Lerebours E. Predicting factors of fistula healing and clinical remission after infliximab-based combined therapy for perianal fistulizing Crohn\u2019s disease. Dig Dis Sci. 2009;54:1746\u20131752. doi:\n                    https:\/\/doi.org\/10.1007\/s10620-008-0545-y","journal-title":"Dig Dis Sci"},{"key":"5635_CR15","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1463-1318.2012.03124.x","volume":"25","author":"R Antakia","year":"2013","unstructured":"Antakia R, Shorthouse AJ, Robinson K, Lobo AJ. Combined modality treatment for complex fistulating perianal Crohn\u2019s disease. Colorectal Dis. 2013;25:210\u2013216.","journal-title":"Colorectal Dis"},{"key":"5635_CR16","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/00054725-200403000-00005","volume":"10","author":"S Ardizzone","year":"2004","unstructured":"Ardizzone S, Maconi G, Colombo E, Manzionna G, Bollani S, Bianchi Porro G. Perianal fistulae following infliximab treatment: clinical and endosonographic outcome. Inflamm Bowel Dis. 2004;10:91\u201396.","journal-title":"Inflamm Bowel Dis"},{"key":"5635_CR17","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.cgh.2012.12.042","volume":"11","author":"G Bouguen","year":"2013","unstructured":"Bouguen G, Siproudhis L, Gizard E, et al. Long-term outcome of perianal fistulizing Crohn\u2019s disease treated with infliximab. Clin Gastroenterol Hepatol. 2013;11:975\u2013981.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"5635_CR18","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1365-2036.2004.01850.x","volume":"19","author":"O Schroder","year":"2004","unstructured":"Schroder O, Blumenstein I, Schulte-Bockholt A, Stein J. Combining infliximab and methotrexate in fistulizing Crohn\u2019s disease resistant or intolerant to azathioprine. Aliment Pharmacol Ther. 2004;19:295\u2013301.","journal-title":"Aliment Pharmacol Ther"},{"key":"5635_CR19","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1111\/j.1365-2036.2004.02247.x","volume":"20","author":"RL West","year":"2004","unstructured":"West RL, van der Woude CJ, Hansen BE. Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn\u2019s disease with infliximab: a double-blind placebo-controlled study. Aliment Pharmacol Ther. 2004;20:1329\u20131336.","journal-title":"Aliment Pharmacol Ther"},{"key":"5635_CR20","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1136\/gutjnl-2013-304488","volume":"63","author":"P Dewint","year":"2014","unstructured":"Dewint P, Hansen BE, Verhey E, et al. Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn\u2019s disease: a randomised, double-blind, placebo controlled trial (ADAFI). Gut. 2014;63:292\u2013299.","journal-title":"Gut"},{"key":"5635_CR21","unstructured":"Strik A, Lowenberg M, Ponsioen CY, Johanna Buskens C, Bemelman WA, D\u2019Haens G. Higher infliximab and adalimumab serum levels correlate with perianal fistula closure in Crohn\u2019s disease patients. United Eur Gastroenterol. 2017;A79."},{"key":"5635_CR22","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","volume":"151","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264\u2013269.","journal-title":"Ann Intern Med"},{"key":"5635_CR23","doi-asserted-by":"crossref","first-page":"5","DOI":"10.18637\/jss.v049.i05","volume":"49","author":"BC Wallace","year":"2012","unstructured":"Wallace BC, Dahabreh IJ, Trikalinos TA, et al. Closing the gap between methodologists and end-users: R as computational back-end. J Stat Softw. 2012;49:5.","journal-title":"J Stat Softw"},{"key":"5635_CR24","unstructured":"Review Manager (RevMan) [Computer Program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014."},{"key":"5635_CR25","unstructured":"Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from \n                    http:\/\/handbook.cochrane.org\n                    \n                  . Accessed 1 Dec 2018."},{"key":"5635_CR26","unstructured":"Wells G, Shea B, O\u2019Connell J, Robertson J, et al. The Newcastle\u2013Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analysis. 2011. \n                    http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp\n                    \n                  . Accessed 1 Dec 2018."},{"key":"5635_CR27","first-page":"299","volume":"53","author":"G Sciaudone","year":"2010","unstructured":"Sciaudone G, Di Stazio C, Limongelli P, et al. Treatment of complex perianal fistulas in Crohn disease: infliximab, surgery or combined approach. Can J Surg. 2010;53:299\u2013304.","journal-title":"Can J Surg"},{"key":"5635_CR28","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/00054725-200303000-00003","volume":"9","author":"M Regueiro","year":"2003","unstructured":"Regueiro M, Mardini H. Treatment of perianal fistulizing Crohn\u2019s disease with infliximab alone or as an adjunct to exam under anesthesia with seton placement. Inflamm Bowel Dis. 2003;9:98\u2013103.","journal-title":"Inflamm Bowel Dis"},{"key":"5635_CR29","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1046\/j.1572-0241.2003.04009.x","volume":"99","author":"I Rasul","year":"2004","unstructured":"Rasul I, Wilson SR, MacRae H, Irwin S, Greenberg GR. Clinical and radiological responses after infliximab treatment for perianal fistulizing Crohn\u2019s disease. Am J Gastroenterol. 2004;99:82\u201388.","journal-title":"Am J Gastroenterol"},{"key":"5635_CR30","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/00054725-200407000-00004","volume":"10","author":"DS Fefferman","year":"2004","unstructured":"Fefferman DS, Lodhavia PJ, Alsahli M, et al. Smoking and immunomodulators do not influence the response or duration of response to infliximab in Crohn\u2019s disease. Inflamm Bowel Dis. 2004;10:346\u2013351.","journal-title":"Inflamm Bowel Dis"},{"key":"5635_CR31","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/apt.13970","volume":"45","author":"AJ Yarur","year":"2017","unstructured":"Yarur AJ, Kanagala V, Stein DJ, et al. Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn\u2019s disease. Aliment Pharmacol Ther. 2017;45:933\u2013940.","journal-title":"Aliment Pharmacol Ther"},{"key":"5635_CR32","first-page":"549","volume":"11","author":"Y Davidov","year":"2017","unstructured":"Davidov Y, Ungar B, Bar-Yoseph H, et al. Association of induction infliximab levels with clinical response in perianal Crohn\u2019s disease. J Crohns Colitis. 2017;11:549\u2013555.","journal-title":"J Crohns Colitis"},{"key":"5635_CR33","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1093\/ecco-jcc\/jjy087","volume":"12","author":"FM Ruemmele","year":"2018","unstructured":"Ruemmele FM, Rosh J, Faubion WA, et al. Efficacy of adalimumab for treatment of perianal fistula in children with moderately to severely active Crohn\u2019s disease: results from IMAgINE 1 and IMAgINE 2. J Crohns Colitis. 2018;12:1249\u20131254.","journal-title":"J Crohns Colitis"},{"key":"5635_CR34","doi-asserted-by":"crossref","first-page":"S508","DOI":"10.1016\/S0016-5085(11)62108-2","volume":"140","author":"DL Goldner","year":"2011","unstructured":"Goldner DL, Shenoy-Bhangle AS, Gee MS, Winter HS, Israel EJ. Clinical and radiological response to anti-TNF alpha treatment for perianal fistulizing Crohn\u2019s disease in one institution in pediatric patients. Gastroenterology. 2011;140:S508\u2013S509.","journal-title":"Gastroenterology"},{"key":"5635_CR35","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1093\/ibd\/izy217","volume":"25","author":"W El-Matary","year":"2019","unstructured":"El-Matary W, Walters TD, Huynh HQ, et al. Higher postinduction infliximab serum trough levels are associated with healing of fistulizing perianal Crohn\u2019s disease in children. Inflamm Bowel Dis. 2019;25:150\u2013155.","journal-title":"Inflamm Bowel Dis"},{"key":"5635_CR36","first-page":"1745692","volume":"2017","author":"Y-M Fu","year":"2017","unstructured":"Fu Y-M, Chen M, Liao A-J. A meta-analysis of adalimumab for fistula in Crohn\u2019s disease. Gastroenterol Res Pract. 2017;2017:1745692.","journal-title":"Gastroenterol Res Pract"},{"key":"5635_CR37","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1097\/MIB.0000000000000377","volume":"21","author":"DA Schwartz","year":"2015","unstructured":"Schwartz DA, Ghazi LJ, Regueiro M. Guidelines for medical treatment of Crohn\u2019s perianal fistulas: critical evaluation of therapeutic trials. Inflamm Bowel Dis. 2015;21:737\u2013752.","journal-title":"Inflamm Bowel Dis"},{"key":"5635_CR38","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1111\/j.1463-1318.2012.02944.x","volume":"14","author":"G El-Gazzaz","year":"2012","unstructured":"El-Gazzaz G, Hull T, Church JM. Biological immunomodulators improve the healing rate in surgically treated perianal Crohn\u2019s fistulas. Colorectal Dis. 2012;14:1217\u20131223.","journal-title":"Colorectal Dis"},{"key":"5635_CR39","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1111\/j.1463-1318.2010.02234.x","volume":"13","author":"WB Gaertner","year":"2011","unstructured":"Gaertner WB, Madoff RD, Spencer MP, Mellgren A, Goldberg SM, Lowry AC. Results of combined medical and surgical treatment of recto-vaginal fistula in Crohn\u2019s disease. Colorectal Dis. 2011;13:678\u2013683.","journal-title":"Colorectal Dis"},{"key":"5635_CR40","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s10350-004-6611-4","volume":"46","author":"DR Topstad","year":"2003","unstructured":"Topstad DR, Panaccione R, Heine JA, Johnson DR, MacLean AR, Buie WD. Combined seton placement, infliximab infusion, and maintenance immunosuppressives improve healing rate in fistulizing anorectal Crohn\u2019s disease: a single center experience. Dis Colon Rectum. 2003;46:577\u2013583.","journal-title":"Dis Colon Rectum"},{"key":"5635_CR41","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1463-1318.2004.00749.x","volume":"7","author":"C Talbot","year":"2005","unstructured":"Talbot C, Sagar PM, Johnston MJ, Finan PJ, Burke D. Infliximab in the surgical management of complex fistulating anal Crohn\u2019s disease. Colorectal Dis. 2005;7:164\u2013168.","journal-title":"Colorectal Dis"},{"key":"5635_CR42","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1007\/s10350-006-0656-5","volume":"49","author":"SA Hyder","year":"2006","unstructured":"Hyder SA, Travis SPL, Jewell DP, McC Mortensen NJ, George BD. Fistulating anal Crohn\u2019s disease: results of combined surgical and infliximab treatment. Dis Colon Rectum. 2006;49:1837\u20131841.","journal-title":"Dis Colon Rectum"},{"key":"5635_CR43","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1097\/MIB.0000000000001243","volume":"23","author":"DA Schwartz","year":"2017","unstructured":"Schwartz DA, Wang A, Ozbay B, et al. Comparison of health care utilization and costs between patients with perianal fistulizing Crohn\u2019s disease treated with biologics with or without previous seton placement. Inflamm Bowel Dis. 2017;23:1860\u20131866.","journal-title":"Inflamm Bowel Dis"},{"key":"5635_CR44","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S0002-9270(02)05909-9","volume":"98","author":"G Assche van","year":"2003","unstructured":"van Assche G, Vanbeckevoort D, Bielen D, et al. Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn\u2019s disease. Am J Gastroenterol. 2003;98:332\u2013339.","journal-title":"Am J Gastroenterol"},{"key":"5635_CR45","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s10350-004-6111-6","volume":"45","author":"AA Bodegraven van","year":"2002","unstructured":"van Bodegraven AA, Sloots CEJ, Felt-Bersma RJF, Meuwissen SG. Endosonographic evidence of persistence of Crohn\u2019s disease-associated fistulas after infliximab treatment, irrespective of clinical response. Dis Colon Rectum. 2002;45:39\u201345.","journal-title":"Dis Colon Rectum"},{"key":"5635_CR46","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1007\/s10350-004-6795-7","volume":"46","author":"T Lecomte","year":"2003","unstructured":"Lecomte T, Contou J-F, Beaugerie L, et al. Predictive factors of response of perianal Crohn\u2019s disease to azathioprine or 6-mercaptopurine. Dis Colon Rectum. 2003;46:1469\u20131475.","journal-title":"Dis Colon Rectum"},{"key":"5635_CR47","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","volume":"362","author":"J-F Colombel","year":"2010","unstructured":"Colombel J-F, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn\u2019s disease. N Engl J Med. 2010;362:1383\u20131395.","journal-title":"N Engl J Med"},{"key":"5635_CR48","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/j.gastro.2013.10.052","volume":"146","author":"R Panaccione","year":"2014","unstructured":"Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014;146:392\u2013393.","journal-title":"Gastroenterology"},{"key":"5635_CR49","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1093\/ecco-jcc\/jjw152","volume":"10","author":"T Matsumoto","year":"2016","unstructured":"Matsumoto T, Motoya S, Watanabe K, et al. Adalimumab monotherapy and a combination with azathioprine for Crohn\u2019s disease: a prospective. Randomized Trial J Crohns Colitis. 2016;10:1259\u20131266.","journal-title":"Randomized Trial J Crohns Colitis"},{"key":"5635_CR50","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/j.cgh.2017.02.005","volume":"15","author":"Y Qiu","year":"2017","unstructured":"Qiu Y, Mao R, Chen B-L, et al. Effects of combination therapy with immunomodulators on trough levels and antibodies against tumor necrosis factor antagonists in patients with inflammatory bowel disease: a meta-analysis. Clin Gastroenterol Hepatol. 2017;15:1359\u20131372.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"5635_CR51","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/ibd.21405","volume":"17","author":"P Roumeguere","year":"2011","unstructured":"Roumeguere P, Bouchard D, Pigot F, et al. Combined approach with infliximab, surgery, and methotrexate in severe fistulizing anoperineal Crohn\u2019s disease: results from a prospective study. Inflamm Bowel Dis. 2011;17:69\u201376.","journal-title":"Inflamm Bowel Dis"},{"key":"5635_CR52","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1097\/MIB.0000000000000409","volume":"21","author":"DM Wiese","year":"2015","unstructured":"Wiese DM, Beaulieu D, Slaughter JC, et al. Use of endoscopic ultrasound to guide adalimumab treatment in perianal Crohn\u2019s disease results in faster fistula healing. Inflamm Bowel Dis. 2015;21:1594\u20131599.","journal-title":"Inflamm Bowel Dis"},{"key":"5635_CR53","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/apt.14969","volume":"48","author":"S Sebastian","year":"2018","unstructured":"Sebastian S, Black C, Pugliese D, et al. The role of multimodal treatment in Crohn\u2019s disease patients with perianal fistula: a multicentre retrospective cohort study. Aliment Pharmacol Ther. 2018;48:941\u2013950.","journal-title":"Aliment Pharmacol Ther"},{"key":"5635_CR54","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/ajg.2017.21","volume":"112","author":"K Papamichael","year":"2017","unstructured":"Papamichael K, Cheifetz AS. Therapeutic drug monitoring in IBD: the new standard-of-care for anti-TNF therapy. Am J Gastroenterol. 2017;112:673\u2013676.","journal-title":"Am J Gastroenterol"},{"key":"5635_CR55","first-page":"2350","volume":"97","author":"J Martinez-Borra","year":"2002","unstructured":"Martinez-Borra J, Lopez-Larrea C, Gonzalez S, et al. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn\u2019s disease. Am J Gastroenterol. 2002;97:2350\u20132356.","journal-title":"Am J Gastroenterol"},{"key":"5635_CR56","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.cgh.2015.10.025","volume":"14","author":"B Ungar","year":"2016","unstructured":"Ungar B, Levy I, Yavne Y, et al. Optimizing anti-TNF-alpha therapy: serum levels of infliximab and adalimumab are associated with mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2016;14:550\u2013552.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"5635_CR57","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1053\/j.gastro.2017.07.032","volume":"153","author":"JD Feuerstein","year":"2017","unstructured":"Feuerstein JD, Nguyen GC, Kupfer SS, et al. American gastroenterological association institute guideline on therapeutic drug monitoring in inflammatory bowel disease. Gastroenterology. 2017;153:827\u2013834.","journal-title":"Gastroenterology"},{"key":"5635_CR58","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.1016\/S0016-5085(17)30701-1","volume":"152","author":"T Greener","year":"2017","unstructured":"Greener T, Kabakchiev B, Silverberg MS. High Infliximab levels are not associated with a higher risk of infection in IBD patients. Gastroenterology. 2017;152:S108.","journal-title":"Gastroenterology"},{"key":"5635_CR59","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1097\/DCR.0000000000001093","volume":"61","author":"AL Lightner","year":"2018","unstructured":"Lightner AL, Wang Z, Zubair AC, et al. A systematic review and meta-analysis of mesenchymal stem cell injections for the treatment of perianal Crohn\u2019s disease: progress made and future directions. Dis Colon Rectum. 2018;61:629\u2013640.","journal-title":"Dis Colon Rectum"},{"key":"5635_CR60","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/S0140-6736(16)31203-X","volume":"388","author":"J Panes","year":"2016","unstructured":"Panes J, Garcia-Olmo D, van Assche G, et al. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn\u2019s disease: a phase 3 randomised, double-blind controlled trial. Lancet. 2016;388:1281\u20131290.","journal-title":"Lancet"},{"key":"5635_CR61","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.cgh.2010.10.022","volume":"9","author":"K Karmiris","year":"2011","unstructured":"Karmiris K, Bielen D, Vanbeckevoort D, et al. Long-term monitoring of infliximab therapy for perianal fistulizing Crohn\u2019s disease by using magnetic resonance imaging. Clin Gastroenterol Hepatol. 2011;9:130\u2013136.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"5635_CR62","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.3748\/wjg.v23.i23.4285","volume":"23","author":"L Thomassin","year":"2017","unstructured":"Thomassin L, Armengol-Debeir L, Charpentier C, et al. Magnetic resonance imaging may predict deep remission in patients with perianal fistulizing Crohn\u2019s disease. World J Gastroenterol. 2017;23:4285\u20134292.","journal-title":"World J Gastroenterol"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-019-05635-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-019-05635-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-019-05635-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,25]],"date-time":"2020-04-25T23:07:02Z","timestamp":1587856022000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-019-05635-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,27]]},"references-count":62,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["5635"],"URL":"https:\/\/doi.org\/10.1007\/s10620-019-05635-1","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,27]]},"assertion":[{"value":"9 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study did not involve research involving human participants or animals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}}]}}